These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9675089)

  • 21. [3H][beta-Ala8]neurokinin A-(4-10): a novel, selective radioligand for the tachykinin NK2 receptor.
    Goso C; Astolfi M; Parlani M; Manzini S
    Eur J Pharmacol; 1995 Dec; 294(1):239-45. PubMed ID: 8788437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tachykinin peptides affect differently the second messenger pathways after binding to CHO-expressed human NK-1 receptors.
    Sagan S; Chassaing G; Pradier L; Lavielle S
    J Pharmacol Exp Ther; 1996 Mar; 276(3):1039-48. PubMed ID: 8786533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tachykinin NK2 receptors: characterization in the rat small intestine by the use of a peptide agonist and a nonpeptide antagonist as radioligands.
    Renzetti AR; Criscuoli M; Maggi CA
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Jul; 356(1):139-44. PubMed ID: 9228201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist.
    Ransom RW; Harrell CM; Reiss DR; Murphy KL; Chang RS; Hess JF; Miller PJ; O'Malley SS; Hey PJ; Kunapuli P; Su DS; Markowitz MK; Wallace MA; Raab CE; Jones AN; Dean DC; Pettibone DJ; Freidinger RM; Bock MG
    Eur J Pharmacol; 2004 Sep; 499(1-2):77-84. PubMed ID: 15363953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular determinants of peptide and nonpeptide NK-2 receptor antagonists binding sites of the human tachykinin NK-2 receptor by site-directed mutagenesis.
    Giolitti A; Cucchi P; Renzetti AR; Rotondaro L; Zappitelli S; Maggi CA
    Neuropharmacology; 2000 Jun; 39(8):1422-9. PubMed ID: 10818258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological characterization of a new class of nonpeptide neurokinin A antagonists that demonstrate species selectivity.
    Aharony D; Buckner CK; Ellis JL; Ghanekar SV; Graham A; Kays JS; Little J; Meeker S; Miller SC; Undem BJ
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1216-21. PubMed ID: 7562491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological characterization of tachykinin NK2 receptors on isolated human urinary bladder, prostatic urethra and prostate.
    Palea S; Corsi M; Artibani W; Ostardo E; Pietra C
    J Pharmacol Exp Ther; 1996 May; 277(2):700-5. PubMed ID: 8627548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Occurrence and pharmacological characterization of four human tachykinin NK2 receptor variants.
    Ahlstedt I; Engberg S; Smith J; Perrey C; Moody A; Morten J; Lagerström-Fermér M; Drmota T; von Mentzer B; Påhlman I; Lindström E
    Biochem Pharmacol; 2008 Aug; 76(4):476-81. PubMed ID: 18601911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
    Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor.
    Bianchi BR; El Kouhen R; Neelands TR; Lee CH; Gomtsyan A; Raja SN; Vaidyanathan SN; Surber B; McDonald HA; Surowy CS; Faltynek CR; Moreland RB; Jarvis MF; Puttfarcken PS
    J Pharmacol Exp Ther; 2007 Oct; 323(1):285-93. PubMed ID: 17660385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MEN16132, a novel potent and selective nonpeptide antagonist for the human bradykinin B2 receptor. In vitro pharmacology and molecular characterization.
    Cucchi P; Meini S; Bressan A; Catalani C; Bellucci F; Santicioli P; Lecci A; Faiella A; Rotondaro L; Giuliani S; Giolitti A; Quartara L; Maggi CA
    Eur J Pharmacol; 2005 Dec; 528(1-3):7-16. PubMed ID: 16324696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional characterization of the human neurokinin receptors NK1, NK2, and NK3 based on a cellular assay system.
    Stratowa C; Machat H; Burger E; Himmler A; Schafer R; Spevak W; Weyer U; Wiche-Castanon M; Czernilofsky AP
    J Recept Signal Transduct Res; 1995; 15(1-4):617-30. PubMed ID: 8903968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterisation, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonists.
    Hagan RM; Beresford IJ; Stables J; Dupere J; Stubbs CM; Elliott PJ; Sheldrick RL; Chollet A; Kawashima E; McElroy AB
    Regul Pept; 1993 Jul; 46(1-2):9-19. PubMed ID: 8210508
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacological evaluation of alpha and beta human tachykinin NK(2) receptor splice variants expressed in CHO cells.
    Bellucci F; Meini S; Catalioto RM; Catalani C; Giuliani S; Quartara L; Giolitti A; Faiella A; Rotondaro L; Candenas ML; Pinto FM; Maggi CA
    Eur J Pharmacol; 2004 Sep; 499(3):229-38. PubMed ID: 15381044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GR159897, a potent non-peptide antagonist at tachykinin NK2 receptors.
    Beresford IJ; Sheldrick RL; Ball DI; Turpin MP; Walsh DM; Hawcock AB; Coleman RA; Hagan RM; Tyers MB
    Eur J Pharmacol; 1995 Jan; 272(2-3):241-8. PubMed ID: 7713168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of guinea pig pulmonary neurokinin type 1 receptors using a novel antagonist ligand, [3H]FK888.
    Miyayasu K; Mak JC; Nishikawa M; Barnes PJ
    Mol Pharmacol; 1993 Sep; 44(3):539-44. PubMed ID: 7690449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the binding sites of [3H]SR 48968, a potent nonpeptide radioligand antagonist of the neurokinin-2 receptor.
    Emonds-Alt X; Golliot F; Pointeau P; Le Fur G; Breliere JC
    Biochem Biophys Res Commun; 1993 Mar; 191(3):1172-7. PubMed ID: 7682062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The non-peptide tachykinin NK2 receptor antagonist SR 48968 interacts with human, but not rat, cloned tachykinin NK3 receptors.
    Chung FZ; Wu LH; Vartanian MA; Watling KJ; Guard S; Woodruff GN; Oxender DL
    Biochem Biophys Res Commun; 1994 Feb; 198(3):967-72. PubMed ID: 8117304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of tachykinins on rapidly adapting pulmonary stretch receptors and total lung resistance in anesthetized, artificially ventilated rabbits.
    Matsumoto S; Takeda M; Saiki C; Takahashi T; Ojima K
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1026-31. PubMed ID: 9399972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Point mutation increases a form of the NK1 receptor with high affinity for neurokinin A and B and septide.
    Ciucci A; Palma C; Manzini S; Werge TM
    Br J Pharmacol; 1998 Sep; 125(2):393-401. PubMed ID: 9786514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.